Effects of a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Fluvastatin, on Coronary Spasm After Withdrawal of Calcium-Channel Blockers
Hirofumi Yasue(Kumamoto City Hospital), Yoshihiko Saito(National Archives and Records Administration), Hisao Ogawa(Kumamoto University Hospital), Minoru Horie(Nagahama City Hospital), Shiroh Uemura(Nara Medical University), Shuichi Ohshima(Kumamoto Chuo Hospital), Masafumi Nakayama(Kumamoto University), Youichi Hokamura(Kumamoto City Hospital), Yuji Mizuno(Saiseikai Kumamoto Hospital), Seiji Hokimoto(Kumamoto University), Hitoshi Nakagawa(Saiseikai Kumamoto Hospital), Teruhiko Itoh(Saiseikai Kumamoto Hospital), Kiyotaka Kugiyama(University of Yamanashi), Masaki Harada(Kyoto University), Michihiro Yoshimura(Jikei University School of Medicine), Takasi Honda(Saiseikai Kumamoto Hospital), Shinji Tayama(Saiseikai Kumamoto Hospital), Eisaku Harada(Saiseikai Kumamoto Hospital)
Cited by 177
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|753
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention
|Journal of the American College of Cardiology|2015|449